SCIENCE 37 HOLDINGS INC (SNCE)
US8086442071 - Common Stock
SCIENCE 37 HOLDINGS INC
NASDAQ:SNCE (3/11/2024, 6:05:35 PM)
After market: 5.7203 -0.03 (-0.52%)5.75
+0.02 (+0.35%)
Company Profile
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
Company Info
SCIENCE 37 HOLDINGS INC
800 Park Offices Drive, Suite 3606
RESEARCH TRIANGLE PARK NORTH CAROLINA
P: 19843773737
CEO: Andrew McDonald
Employees: 460
Website: https://lifesciacquisition.com
SNCE News
a month ago - Science 37, Inc.Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region
a month ago - Science 37, Inc.Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NCScience 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials....
2 months ago - Science 37, Inc.Science 37 Enrolls 42% of Trial Cohort in 8 WeeksScience 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.
2 months ago - Science 37, Inc.Science 37 Quickly Impacts Performance in Under-Enrolling Clinical TrialsNearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities
2 months ago - Science 37, Inc.Science 37 Quickly Impacts Performance in Under-Enrolling Clinical TrialsNearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities....
3 months ago - Science 37, Inc.CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical TrialScience 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions
SNCE Twits
Here you can normally see the latest stock twits on SNCE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
